Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 10th Preview)
-
Biopharma M&A and dealmaking acceleration
Biopharma M&A activity surged in March 2026, with big pharma buyers completing seven transactions worth more than $1 billion each across a 12-day stretch, according to deal tracking summarized in the report. The rebound is being interpreted by market watchers as a signal that 2026 could bring sustained deal momentum rather than a one-off spike. The surge included a series of large, headline transactions: Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, Eli Lilly moved to buy Centessa Pharmaceuticals in a $6.3 billion deal, and Biogen announced a $5.6 billion acquisition of Apellis. Jefferies also tracked 14 deals of at least $500 million in Q1, versus 32 across all of 2025, suggesting a higher bar for deal sizes. Gilead, Otsuka, Novartis, and others also participated in the late-month flurry, underlining Big Pharma’s push to refresh pipelines. The report frames the renewed appetite as potentially supporting secondary offerings and IPOs, as acquirers return capital and validate asset classes for investors.
-
Partnering and expansion in targeted protein degradation
Roche escalated its degrader strategy with a new collaboration with C4 Therapeutics focused on degrader-antibody conjugates (DACs), combining C4’s targeted protein degradation payloads with Roche’s antibody-drug conjugate delivery expertise. Roche will pay $20 million upfront and may contribute more than $1 billion across discovery, regulatory, and commercial milestones. The pact aims to generate DAC candidates against two undisclosed oncology targets, with an option to add a third target. C4 will design the degrader payloads using its Torpedo platform, while Roche will select and engineer antibodies; the partners plan to advance candidates through preclinical studies and onward. Roche is positioning DACs as a way to address modality limitations seen in traditional ADCs, including toxicity and resistance patterns driven by cytotoxic payloads. The deal adds to a growing set of Big Pharma efforts to diversify pipelines using protein-degradation mechanisms.
-
Gilead expands molecular-glue oncology pipeline via Kymera option
Gilead exercised a $45 million option on Kymera Therapeutics’ preclinical molecular-glue degrader program, positioning the company to advance an oral CDK2 degrader into IND-enabling work. Under the agreement, Gilead gains global rights to KT-200, a candidate designed to degrade CDK2 with low-nanomolar activity. The move more than doubles Kymera’s total proceeds from the partnership and sets up potential development, regulatory, and commercial milestones of up to $665 million. Gilead is expected to run IND-enabling studies with a stated goal of filing to test the candidate in humans next year. Kymera’s differentiation is based on molecular-glue mechanism rather than conventional small-molecule kinase inhibition. The report notes mounting industry interest in CDK2 in the wake of uneven outcomes with CDK4/6 inhibitors and the search for better-controlled next steps in oncology settings.
-
AI-enabled real-world data access for oncology development
Tempus and Gilead expanded their data partnership, giving Gilead broader access to Tempus’ multimodal real-world cancer datasets and the Tempus AI platform. The update builds on an existing deal in which Gilead could use de-identified patient data for trial design and biomarker strategy. Under the expanded collaboration, Gilead will access more multimodal data across indications and use Tempus’ Lens analytics environment, which integrates tumor-normal DNA/RNA data and H&E slide information. Tempus said Lens can apply cohort filtering, simulate clinical trials, and visualize datasets, and it includes a large language model integrated into the platform. Tempus framed the expanded access as enabling “signal in the noise” searches across very large datasets, and the partnership adds another example of pharma-company RWD strategy focused on AI-driven cohorting and development decisions.
-
Regulatory review shift for AI diagnostic devices
The FDA denied a petition from Harrison.ai seeking partial exemption from premarket review for certain diagnostic and detection AI devices, provided the manufacturer has 510(k) clearance for a similar category. The decision maintains what the FDA described as the regulatory status quo and requires a robust postmarket plan. The denial matters for developers pursuing AI-enabled diagnostics because it signals continued constraints on pathways that would reduce upfront review requirements. It also increases the compliance burden for firms aiming to reuse existing 510(k)-cleared device frameworks for new AI use cases. For biotech and med-tech investors, the action is another datapoint in how the FDA is calibrating risk-based oversight for adaptive or software-centric diagnostic tools.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.